These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 11753908

  • 21. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, Rimola A, Bernardos A, Otero S, Maldonado J, Herrero JI, Barrao E, Domínguez-Granados R.
    Liver Transpl; 2009 Nov 15; 15(11):1542-52. PubMed ID: 19877219
    [Abstract] [Full Text] [Related]

  • 25. Daclizumab induction therapy in liver transplant recipients with renal insufficiency.
    Asrani SK, Kim WR, Pedersen RA, Charlton MR, Kremers WK, Therneau TM, Rosen CB, Dean PG.
    Aliment Pharmacol Ther; 2010 Sep 15; 32(6):776-86. PubMed ID: 20659283
    [Abstract] [Full Text] [Related]

  • 26. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G.
    Transplant Proc; 2007 Sep 15; 39(7):2163-6. PubMed ID: 17889125
    [Abstract] [Full Text] [Related]

  • 27. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients.
    Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, Samuel D, Vanlemmens C, Neau-Cransac M, Salamé E, Chazouillères O, Declerck N, Pageaux GP, Dubel L, Rostaing L.
    Transplantation; 2010 Jun 27; 89(12):1504-10. PubMed ID: 20495510
    [Abstract] [Full Text] [Related]

  • 28. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection.
    Zekry A, Gleeson M, Guney S, McCaughan GW.
    Liver Transpl; 2004 Jan 27; 10(1):52-7. PubMed ID: 14755778
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar 27; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 33. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS.
    Transplantation; 2000 May 15; 69(9):1867-72. PubMed ID: 10830224
    [Abstract] [Full Text] [Related]

  • 34. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.
    Liver Transpl; 2013 Aug 15; 19(8):896-906. PubMed ID: 23696054
    [Abstract] [Full Text] [Related]

  • 35. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 15; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 36. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
    Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE.
    Transplantation; 2004 Oct 27; 78(8):1212-7. PubMed ID: 15502722
    [Abstract] [Full Text] [Related]

  • 37. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A, Jiménez C, Ortega P, Abradelo M, Gimeno A, Calvo J, Cambra F, -Sterup RL, Morales JM, Moreno E.
    Transplant Proc; 2008 Nov 27; 40(9):2962-4. PubMed ID: 19010160
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS.
    Liver Transpl; 2005 Sep 27; 11(9):1064-72. PubMed ID: 16123958
    [Abstract] [Full Text] [Related]

  • 39. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study.
    Fahlke J, Wolff S, Mantke R, Pross M, Weiss G, Buerger T, Lippert H.
    Transplant Proc; 2002 Jun 27; 34(4):1242-4. PubMed ID: 12072328
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G, Burke GW, Suzart K, Vaidya A, Roth D, Kupin W, Mattiazzi A, Rosen A, Esquenazi V, Miller J.
    Transplant Proc; 2003 Mar 27; 35(2):873-4. PubMed ID: 12644172
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.